JP4201253B2 - 薬学的活性物質に潜在性を提供する方法 - Google Patents

薬学的活性物質に潜在性を提供する方法 Download PDF

Info

Publication number
JP4201253B2
JP4201253B2 JP2002555832A JP2002555832A JP4201253B2 JP 4201253 B2 JP4201253 B2 JP 4201253B2 JP 2002555832 A JP2002555832 A JP 2002555832A JP 2002555832 A JP2002555832 A JP 2002555832A JP 4201253 B2 JP4201253 B2 JP 4201253B2
Authority
JP
Japan
Prior art keywords
lap
nucleic acid
fusion protein
mmp
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002555832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004520031A (ja
JP2004520031A5 (enExample
Inventor
ユチ チャーナジョフスキー
ハンナ スティナ ドレジャ
ジリアン アダムス
Original Assignee
クイーンメリー アンド ウエストフィールド カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クイーンメリー アンド ウエストフィールド カレッジ filed Critical クイーンメリー アンド ウエストフィールド カレッジ
Publication of JP2004520031A publication Critical patent/JP2004520031A/ja
Publication of JP2004520031A5 publication Critical patent/JP2004520031A5/ja
Application granted granted Critical
Publication of JP4201253B2 publication Critical patent/JP4201253B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002555832A 2001-01-09 2002-01-09 薬学的活性物質に潜在性を提供する方法 Expired - Fee Related JP4201253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/756,283 US6942853B2 (en) 2001-01-09 2001-01-09 Latent fusion protein
GBGB0100551.1A GB0100551D0 (en) 2001-01-09 2001-01-09 Protein
PCT/GB2002/000068 WO2002055098A2 (en) 2001-01-09 2002-01-09 Latency associated peptide for providing latency to pharmaceutically active proteins

Publications (3)

Publication Number Publication Date
JP2004520031A JP2004520031A (ja) 2004-07-08
JP2004520031A5 JP2004520031A5 (enExample) 2005-12-22
JP4201253B2 true JP4201253B2 (ja) 2008-12-24

Family

ID=26245544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002555832A Expired - Fee Related JP4201253B2 (ja) 2001-01-09 2002-01-09 薬学的活性物質に潜在性を提供する方法

Country Status (10)

Country Link
US (1) US6942853B2 (enExample)
EP (1) EP1349944B1 (enExample)
JP (1) JP4201253B2 (enExample)
AT (1) ATE293169T1 (enExample)
AU (1) AU2002219345B2 (enExample)
DE (1) DE60203692T2 (enExample)
DK (1) DK1349944T3 (enExample)
ES (1) ES2240740T3 (enExample)
GB (1) GB0100551D0 (enExample)
WO (1) WO2002055098A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
AU2003217415B2 (en) * 2002-02-14 2009-01-08 William J Rutter Chimeric molecules for cleavage in a treated host
AU2006302587A1 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
DE102006009324A1 (de) 2006-03-01 2007-09-06 Dr.Ing.H.C. F. Porsche Ag Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts
EP2572734B1 (en) 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
FR2932190A1 (fr) * 2008-06-10 2009-12-11 Commissariat Energie Atomique Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease
EP3348275A3 (en) 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
EP2878308B1 (en) * 2013-12-02 2018-10-31 Thomas Harder Agents and methods for the suppression of T cell activation
GB201411506D0 (en) * 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
MX2020012252A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
KR20250154552A (ko) * 2018-09-27 2025-10-28 실리오 디벨럽먼트, 인크. 마스킹된 사이토카인 폴리펩타이드
ES2780274A1 (es) * 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2021097376A1 (en) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
CN115667523A (zh) * 2020-04-10 2023-01-31 西托姆克斯治疗公司 可活化细胞因子构建体和相关组合物以及方法
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
CA2003886A1 (en) 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
CA2068204C (en) 1989-11-22 2002-02-12 Arthur Levinson Latency associated peptides and uses therefor
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
PT698094E (pt) 1993-05-12 2004-05-31 Inst Genetics Llc Composicoes de bmp-11
CA2151547C (en) 1994-06-10 2010-10-12 Elliott A. Gruskin Recombinant chimeric proteins and methods of use thereof
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
WO1997012048A1 (en) * 1995-09-27 1997-04-03 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
JP4566290B2 (ja) * 1997-04-30 2010-10-20 ツインストランド・ホールディングス・インコーポレイテッド 癌、ウイルスまたは寄生虫感染を治療するためのリシン様毒素変異体
GB2324960A (en) 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
AU1103900A (en) 1998-10-07 2000-04-26 Stryker Corporation Modified tgf-beta superfamily proteins
AU8911101A (en) * 2000-09-11 2002-03-26 Univ Columbia Combinatorial fluorescence energy transfer tags and uses thereof

Also Published As

Publication number Publication date
EP1349944A2 (en) 2003-10-08
AU2002219345B2 (en) 2006-03-16
US6942853B2 (en) 2005-09-13
ES2240740T3 (es) 2005-10-16
JP2004520031A (ja) 2004-07-08
DK1349944T3 (da) 2005-07-25
WO2002055098A3 (en) 2002-11-21
DE60203692T2 (de) 2006-03-02
DE60203692D1 (de) 2005-05-19
GB0100551D0 (en) 2001-02-21
EP1349944B1 (en) 2005-04-13
WO2002055098A2 (en) 2002-07-18
US20020151478A1 (en) 2002-10-17
ATE293169T1 (de) 2005-04-15

Similar Documents

Publication Publication Date Title
JP4201253B2 (ja) 薬学的活性物質に潜在性を提供する方法
AU2002219345A1 (en) Latency associated peptide for providing latency to pharmaceutically active proteins
JP3681069B2 (ja) Ｂｍｐ−１１組成物
US7122352B2 (en) Polynucleotide encoding mammalian cytokine-like polypeptide-10
JPH05503003A (ja) 潜在性関与ペプチドおよびその使用
US20200062814A1 (en) Modified Latency Associated Protein Construct
US20180009865A1 (en) Bmp-2 peptides and methods of use
KR20170026580A (ko) 변형된 폰 빌레브란트 인자
WO1994009812A1 (en) METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
US8357515B2 (en) Latency associated protein construct with aggrecanase sensitive cleavage site
US7307147B2 (en) Latent fusion protein
SK8472003A3 (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
ZA200305237B (en) Latency associated peptide for providing latency to pharmaceutically active proteins
US7265089B2 (en) KGF polypeptide compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080527

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080908

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081003

R150 Certificate of patent or registration of utility model

Ref document number: 4201253

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111017

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121017

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121017

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131017

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees